The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Read more here. Building a skin-care routine for teens and tweens can seem complicated. Puberty is often the first time kids are dealing with acne, blackheads, dry patches, and the general roller ...